The Latest Breaking News from Cronos Group

The cannabis industry is expanding rapidly, but only a few cannabis companies can be winners.

Shares of cannabis companies surge as much as 80 percent after move to classify drug as schedule three substance.

With evolving food consumption trends, favorable government policies and funding, and the adoption of cutting-edge technologies, the agricultural industry is well-placed to experience significant growth in the long run. So, let’s compare prominent agriculture stocks Cronos Group (CRON) and MariMed (MRMD) to identify which is gaining immense popularity among investors.…

Despite the growing market for recreational cannabis, Cronos Group (CRON) has failed to surpass its consensus EPS and revenue estimates during the first quarter. However, given its substantial cash reserves and no long-term debt, is CRON a good buy now? Keep reading.

Organized by the US Cannabis Council (USCC), the Buy Legal campaign is partnering with elected officials, cannabis companies, individuals and organizations to promote a safe, legal and well-regulated industry. 

In September, the Global Cannabis Stock Index closed low on 9/30 and ended the month down 25.9%, wrote Ala

Cronos Group Inc. (NASDAQ: CRON) (TSX:CRON) launched the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the VESIsorb delivery system.

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) reported Tuesday its 2022 first quarter business results with net revenue growth of 101.61% year-over-year, due to the revenue improvements in the Israeli medical market and the Canadian adult-use market.

  Cronos Group (NASDAQ:CRON) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.